Developability assessment is essential for selecting the best monoclonal antibodies (mAbs) candidates for clinical development.
Dr. Elsa Wagner, a senior discovery scientist at Pierre Fabre Laboratories in France, focuses on putting together a comprehensive developability platform for monoclonal antibodies (mAbs) in immuno-oncology. To achieve this, Dr. Wagner needs precise methods to assess key stability parameters, such as thermal unfolding, particle sizing, and aggregation. Faced with large libraries of potential candidates, her priority is to obtain highly accurate and reproducible data for confident decision-making.
In this testimonial, read why she chose the Prometheus Panta instrument for simultaneous measurements of Dynamic Light Scattering (DLS), Differential Scanning Fluorimetry (nanoDSF), Static Light Scattering (SLS), and backreflection.
You’ll learn about:
-
How Pierre Fabre Laboratories approaches developability assessment for mAbs candidates
-
The criteria that guided her decision for the Prometheus Panta as a solution for her developability platform
-
The benefits of combining simultaneous thermal and colloidal stability measurements for confident ranking of mAbs candidates
For more information about Prometheus Panta for biologics developability assessment watch this video.
